- Home
- SWKH vs TLSI Comparison
SWKH vs TLSI Comparison
Compare SWKH & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWKH
- TLSI
- Stock Information
- Founded
- SWKH 1996
- TLSI 2010
- Country
- SWKH United States
- TLSI United States
- Employees
- SWKH N/A
- TLSI N/A
- Industry
- SWKH Diversified Financial Services
- TLSI Medical Specialities
- Sector
- SWKH Finance
- TLSI Health Care
- Exchange
- SWKH Nasdaq
- TLSI Nasdaq
- Market Cap
- SWKH 179.1M
- TLSI 204.0M
- IPO Year
- SWKH 1999
- TLSI N/A
- Fundamental
- Price
- SWKH $15.28
- TLSI $4.56
- Analyst Decision
- SWKH Strong Buy
- TLSI Strong Buy
- Analyst Count
- SWKH 1
- TLSI 5
- Target Price
- SWKH $18.00
- TLSI $10.90
- AVG Volume (30 Days)
- SWKH 15.0K
- TLSI 133.1K
- Earning Date
- SWKH 08-14-2025
- TLSI 08-13-2025
- Dividend Yield
- SWKH N/A
- TLSI N/A
- EPS Growth
- SWKH 51.50
- TLSI N/A
- EPS
- SWKH 1.41
- TLSI N/A
- Revenue
- SWKH $34,906,000.00
- TLSI $32,141,000.00
- Revenue This Year
- SWKH $52.93
- TLSI $55.39
- Revenue Next Year
- SWKH N/A
- TLSI $54.89
- P/E Ratio
- SWKH $10.83
- TLSI N/A
- Revenue Growth
- SWKH 18.02
- TLSI 46.20
- 52 Week Low
- SWKH $12.00
- TLSI $3.50
- 52 Week High
- SWKH $16.24
- TLSI $6.04
- Technical
- Relative Strength Index (RSI)
- SWKH 60.17
- TLSI 39.21
- Support Level
- SWKH $15.07
- TLSI $4.41
- Resistance Level
- SWKH $15.28
- TLSI $4.73
- Average True Range (ATR)
- SWKH 0.17
- TLSI 0.22
- MACD
- SWKH -0.02
- TLSI -0.02
- Stochastic Oscillator
- SWKH 88.37
- TLSI 18.99
About SWKH SWK Holdings Corporation
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.